Immune response to conjugated meningococcal C vaccine in pediatric oncology patients

Pediatric Blood and Cancer

Volumn 49, Issue 7, 2007, Pages 918-923

  Yu, Joyce W ^a   Borkowski, Astrid ^b   Danzig, Lisa ^c   Reiter, Stephanie ^a   Kavan, Peter ^a   Mazer, Bruce D ^a,d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Chiron Behring GmbH & Co   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Antibody response; B lymphocytes; Pediatric cancer; Vaccine

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BACTERICIDAL ACTIVITY; BONE MARROW TRANSPLANTATION; CANADA; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TOLERABILITY; EPIDEMIC; FEMALE; HUMAN; IMMUNE RESPONSE; INFANT; MAINTENANCE THERAPY; MALE; MASS IMMUNIZATION; MENINGOCOCCOSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; NEOPLASMS; SEROLOGIC TESTS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 35648962812     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21174     Document Type: Article

References (31)

1. Weir E. Oh no, not another childhood vaccine. JAMC 2002;166:1064-1066.
2. Maclennan J. Meningococcal group C conjugate vaccines. Arch Dis Child 2001;84:383-386.
3. Whalen CH, Hockin JC, Ryan A, et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992 emergence of a virulent clone of neisseria meningitides. JAMA 1995;273:390-394.
4. Maiden M, Spratt B. Meningococcal conjugate vaccines: New opportunities and new challenges. Lancet 1999;345:615-616.
5. Pollard A, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000;19:333-345.
6. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001;344:1378-1388.
7. Rivest P, Allard R. The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data. Vaccine 2002;20:2533-2656.
8. Hudon N. La Meningite: 350000 jeunes Monteregiens seront vaccines cet automne. Quebec: Regie regional de services en sante et social du Monteregie. 2001.
9. Jones DH. Menjugate (Chiron). Curr Opin Investig Drugs 2001;2:47-49.
10. Weisman SJ, Cates KL, Allegretta GJ, et al. Antibody response to immunization with Haemophilus influenzae type b polysaccharide vaccine in children with cancer. J Pediatr 1987;111:727-729.
11. Ridgway D, Wolff LJ. Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 1993;9:177-1792.
12. Ridgway D, Wolff LJ, Deforest A. Immunization response varies with intensity of acute lymphoblastic leukemia therapy. Am J Dis Child 1991;145:887-891.
13. Feldman S, Gigliotti F, Shenep JL, et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990;161:926-931.
14. Brydak LB, Rokicka-Milewska R, Machala M, et al. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 1998;17:125-129.
15. Spoulou V, Victoratos P, Ioannidis J, et al. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J Infect Dis 2000;182:965-969.
16. Granoff DM, Maslanka SE, Carlone GM, et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5:479-485.
17. MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: A randomized controlled trial. JAMA 1998;280:1685-1689.
18. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-1326.
19. Santos GF, Deck RR, Donnelly J, et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001;8:616-623.
20. McCusker C, Somerville W, Grey V, et al. Specific antibody responses to diptheria/tetanus revaccination in children evaluated for immunodeficiency. Ann Allergy Asthma Immunol 1997;79:145-150.
21. Trotter C, Borrow R, Andrews N, et al. Seroprevalence of meningococcal serogroup C bactericidal antibodies in England and Wales in the pre-vaccination era. Vaccine 2003;21:1094-1098.
22. Maiden M, Stuart J. Carriage of serogroup C meningococcal 1 year after meningococcal C conjugate polysaccharide vaccination. The Lancet 2002;359:1829-1830.
23. De Wals P, De Serres G, Niyonsenga T. The effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001;285:177-181.
24. Alanko S, Salmi T, Pelliniemi T. Recovery of blood T cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994;11:281-292.
25. Alanko S, Pelliniemi T, Salmi T. Recovery of blood B lymphocytes and serum immunoglobulins after chemotherapy for childhood ALL. Cancer 1992;69:1481-1486.
26. Alanko S, Pelliniemi T, Salmi T. Recovery of blood lymphocytes and serum immunoglobulins after treatment of solid tumors in children. Pediatr Hematol Oncol 1994;11:33-45.
27. Mustafa M, Buchanan G, Winick N, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J of Pediatr Hematol Oncol 1998;20:451-457.
28. Hovi L, Valle M, Slimes M, et al. Impaired response to hepatitis B vaccine in children receiving anti-cancer chemotherapy. Pediatr Infect Dis J 1995;14:931-935.
29. Kung F, Orgel H, Wallace W. Antibody production following immunization with diptheria and tetanus toxoid in children receiving chemotherapy during remission of malignant disease. Pediatrics 1984;74:86-89.
30. Nilsson A, De Milito A, Engstrom P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109:e91.
31. Brodtman DH, Rosenthal DW, Redner A, et al. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 2005;146:654-661.